Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418782 · ClinicalTrials.gov registry record · Phase 2
A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
NCT00418782: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT00418782 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 212 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00418782, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
Study Summary
CE-224535 is a new medication being developed as an analgesic and anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate the analgesic and anti inflammatory efficacy and safety of CE 224,535 versus placebo and naproxen treatment in patients with OA knee pain.
Interventions
- DRUG placebo
- DRUG naproxen
- DRUG CE-224535
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Why NCT00418782 stopped before completion
NCT00418782 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00418782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00418782 about?
NCT00418782 is a clinical study titled "A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain". CE-224535 is a new medication being developed as an analgesic and anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate the analgesic and anti inflammatory efficacy and safety of CE 224,535 versus placebo and naproxen tre...
What is the current status of trial NCT00418782?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2007-01. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00418782?
The interventions under investigation include: placebo (DRUG), naproxen (DRUG), CE-224535 (DRUG).
Who is sponsoring clinical trial NCT00418782?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00418782's enrollment target sits among peer trials
212 290th of 2000 higher than 1,711 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia